Changes of serum adiponectin and soluble intercellular adhesion molecule-1 concentrations after smoking cessation

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 6, 2012, Pages 1063-1069

  Tsai, Jaw Shiun ^a,b   Guo, Fei Ran ^a   Chen, Su Chiu ^c   Lue, Bee Horng ^a   Lee, Long Teng ^a   Huang, Kuo Chin ^a   Chen, Chin Ying ^a   Hung, Shou Hung ^a   Chuang, Lee Ming ^a,b,d   Chen, Ching Yu ^a,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Adiponectin; Body weight; Cardiovascular disease; Intercellular adhesion molecule 1; Smoking cessation

Indexed keywords

ADIPONECTIN; COTININE; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MALE; MEDICAL EDUCATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SMOKING CESSATION; STUDENT T TEST; BLOOD; CHEMISTRY; CLINICAL TRIAL; MIDDLE AGED; REGRESSION ANALYSIS; SOLUBILITY;

ADIPONECTIN; ADULT; AGED; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SMOKING CESSATION; SOLUBILITY;

EID: 84867419935     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0852     Document Type: Article

References (47)

1. Mallampalli A, Guntupalli KK. Smoking and systemic disease. Med Clin North Am 2004;88:1431-51.
2. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs 2002;62(Suppl 2):1-9.
3. Peto R. Smoking and death: the past 40 years and the next 40. BMJ 1994;309:937-9.
4. Taylor DH Jr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health 2002;92:990-6.
5. Oren S, Isakov I, Golzman B, Kogan J, Turkot S, Peled R, et al. The influence of smoking cessation on hemodynamics and arterial compliance. Angiology 2006;57:564-8.
6. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking cessation and the risk of stroke in middle-aged men. J Am Med Assoc 1995;274:155-60.
7. Tosteson AN, Weinstein MC, Williams LW, Goldman L. Longterm impact of smoking cessation on the incidence of coronary heart disease. Am J Public Health 1990;80:1481-6.
8. Jatoi NA, Jerrard-Dunne P, Feely J, Mahmud A. Impact of smoking and smoking cessation on arterial stiffness and aortic wave reflection in hypertension. Hypertension 2007;49:981-5.
9. Lu JT, Creager MA. The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med 2004;5:189-93.
10. Perkins KA, Epstein LH, Pastor S. Changes in energy balance following smoking cessation and resumption of smoking in women. J Consult Clin Psychol 1990;58:121-5.
11. Perkins KA. Weight gain following smoking cessation. J Consult Clin Psychol 1993;61:768-77.
12. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992;339:1128-30.
13. Eliasson B, Attvall S, Taskinen MR, Smith U. Smoking cessation improves insulin sensitivity in healthy middle-aged men. Eur J Clin Invest 1997;27:450-6.
14. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. Obes Rev 2004;5:95-103.
15. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005;6:13-21.
16. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002;10:1104-10.
17. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002;13:51-9.
18. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-9.
19. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, et al. Synthetic peroxisome proliferator-activated receptorgamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-80.
20. Pardo IM, Geloneze B, Tambascia MA, Barros AA. Inverse relationship between cord blood adiponectin concentrations and the number of cigarettes smoked during pregnancy. Diabetes Obes Metab 2005;7:144-7.
21. Iwashima Y, Katsuya T, Ishikawa K, Kida I, Ohishi M, Horio T, et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005;45:1094-100.
22. Strauss E, Radziemski A, Gluszek J, Pawlak A. Smoking enhances the decrease of adiponectin level in patients with coronary artery disease, carriers of MTHFR 677T and PON1 55M alleles. Przegl Lek 2010;67:859-65.
23. Kawamoto R, Tabara Y, Kohara K, Miki T, Ohtsuka N, Kusunoki T, et al. Smoking status is associated with serum high molecular adiponectin levels in community-dwelling Japanese men. J Atheroscler Thromb 2010;17:423-30.
24. Otsuka F, Kojima S, Maruyoshi H, Kojima S, Matsuzawa Y, Funahashi T, et al. Smoking cessation is associated with increased plasma adiponectin levels in men. J Cardiol 2009;53:219-25.
25. Efstathiou SP, Skeva II, Dimas C, Panagiotou A, Parisi K, Tzanoumis L, et al. Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population. Atherosclerosis 2009;205:632-6.
26. Inoue K, Takeshima F, Kadota K, Yoda A, Tatsuta Y, Nagaura Y, et al. Early effects of smoking cessation and weight gain on plasma adiponectin levels and insulin resistance. Intern Med 2011;50:707-12.
27. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
28. Takeuchi N, Kawamura T, Kanai A, Nakamura N, Uno T, Hara T, et al. The effect of cigarette smoking on soluble adhesion molecules in middle-aged patients with Type 2 diabetes mellitus. Diabet Med 2002;19:57-64.
29. Scott DA, Stapleton JA, Wilson RF, Sutherland G, Palmer RM, Coward PY, et al. Dramatic decline in circulating intercellular adhesion molecule-1 concentration on quitting tobacco smoking. Blood Cells Mol Dis 2000;26:255-8.
30. Palmer RM, Stapleton JA, Sutherland G, Coward PY, Wilson RF, Scott DA. Effect of nicotine replacement and quitting smoking on circulating adhesion molecule profiles (sICAM-1, sCD44v5, sCD44v6). Eur J Clin Invest 2002;32:852-7.
31. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-6.
32. Takefuji S, Yatsuya H, Tamakoshi K, Otsuka R, Wada K, Matsushita K, et al. Smoking status and adiponectin in healthy Japanese men and women. Prev Med 2007;45:471-5.
33. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 1991;86:1119-27.
34. Treating Tobacco Use and Dependence: 2008 Update. Public Health Service, U. S. Department of Health and Human Services. May 2008. Available from: http://www.surgeongeneral.gov/tobacco. Accessed on 10, Dec, 2011.
35. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39.
36. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age-and sex-specific prediction formulas. Br J Nutr 1991;65:105-14.
37. Tsou PL, Jiang YD, Chang CC, Wei JN, Sung FC, Lin CC, et al. Gender-related differences between adiponectin and insulin resistance in schoolchildren. Diabetes Care 2004;27:308-13.
38. Ferrara CM, Kumar M, Nicklas B, McCrone S, Goldberg AP. Weight gain and adipose tissue metabolism after smoking cessation in women. Int J Obes Relat Metab Disord 2001;25:1322-6.
39. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 2006;60:1697-706.
40. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc 2003;289:1799-804.
41. Nizamutdinova IT, Kim YM, Kim HJ, Seo HG, Lee JH, Chang KC. Carbon monoxide (from CORM-2) inhibits high glucoseinduced ICAM-1 expression via AMP-activated protein kinase and PPAR-gamma activations in endothelial cells. Atherosclerosis 2009;207:405-11.
42. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Assoc 2004;291:1730-7.
43. Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T, et al. Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 2002;51:2964-7.
44. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005;111:747-53.
45. Brownell KD. Diet, exercise and behavioural intervention: the non-pharmacological approach. Eur J Clin Invest 1998;28(Suppl 2):19-21.
46. Jürimäe J, Jürimäe T. Plasma adiponectin concentration in healthy pre-and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. Am J Physiol Endocrinol Metab 2007;293:E42-7.
47. Shand B, Elder P, Scott R, Frampton C, Willis J. Biovariability of plasma adiponectin. Clin Chem Lab Med 2006;44:1264-8